Biotech’s IPO Window Is Reopening—But Only for Companies Wall Street Can Underwrite
The market is thawing, but not in the anything-goes way
Biotech’s AI Race Is No Longer About Models. It’s About Infrastructure.
Roche’s latest Nvidia build is not just another AI headline.
A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads
When Dr. Peter Marks walked out of the FDA’s headquarters
MOST POPULAR
